Letters to the Editor

Update on Treatment of Influenza A and B with Tamiflu



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2001 Feb 15;63(4):635-636.

to the editor: Since the article “Updated Treatment for Influenza A and B”1 was accepted for publication, the U.S. Food and Drug Administration (FDA) has approved two new indications for oseltamivir (Tamiflu).2 The FDA previously approved labeling for oseltamivir only for the treatment of uncomplicated influenza in adults.

The first new indication is the use of oseltamivir in the prevention of influenza in patients 13 years and older. Prophylactic treatment should be initiated within 48 hours of contact with an infected person. The recommended oral dose is 75 mg once daily for at least seven days, but it may be used for up to six weeks.

The second new indication is the treatment of acute illness from uncomplicated influenza in children one year or older who have been symptomatic for no longer than two days.3,4 As with adults, treatment should be initiated within 48 hours of symptom onset. Twice daily dosing is based on body weight, and the drug will be supplied as a “tutti-frutti-tasting” suspension (12 mg per mL). The duration of treatment is five days.3,4 The pediatric suspension formulation was expected to be released in mid-January. Adults who have difficulty swallowing capsules may also prefer the suspension.

Readers should note these important new changes since publication of our article.1

REFERENCES

1. Montalto NJ, Gum K, Ashley JV. Updated treatment for Influenza A and B. Am Fam Phys. 2000;62:2467–76.

2. www.fda.gov/bbs/topics/ANSWERS/ANS01056.html.

3. www.fda.gov/cder/drug/infopage/Tamiflu/

4. Tamiful (oseltamivir phosphate) capsules. Package insert. Nutley, NJ: Roche Laboratories, Inc. Revised December 2000.

Dr. Montalto receives an honorarium and is a member of the Speakers Bureau for Roche Laboratories and Glaxo Wellcome Inc.

editor's note: An updated text and table are available at www.aafp.org.

 

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.



Copyright © 2001 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article